Efficacy of Alectinib in Patients with ALK-Positive NSCLC and Symptomatic or Large CNS Metastases

BACKGROUND: Central nervous system (CNS) metastases represent a significant source of morbidity and mortality for patients with ALK-positive non-small cell lung cancer (NSCLC). Alectinib has demonstrated robust CNS activity in both crizotinib-naïve and crizotinib-resistant settings. However, the CNS...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Thorac Oncol
Autores principales: Lin, Jessica J., Jiang, Ginger Y., Joshipura, Nencyben, Ackil, Jennifer, Digumarthy, Subba R., Rincon, Sandra P., Yeap, Beow Y., Gainor, Justin F., Shaw, Alice T.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2018
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6440803/
https://ncbi.nlm.nih.gov/pubmed/30529198
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2018.12.002
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares